|

NT-I7 Clinical Trials

2 actively recruiting trials across 1 location

▲ +1 trial since June 2026

Also known as: Efineptakin alfa, Recombinant human IL-7

Pipeline

Phase 1: 2

Top Sponsors

  • Washington University School of Medicine2

Indications

  • Cancer2
  • Multiple Myeloma, Refractory1
  • Multiple Myeloma in Relapse1
  • Large B-cell Lymphoma1
  • Multiple Myeloma1

St Louis, Missouri2 trials

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of Medicine

Phase 1
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

Washington University School of Medicine

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.